Immuron Submits IND Application To FDA for Travelan
05 déc. 2022 06h00 HE
|
Immuron Limited
Highlights: Investigational New Drug (IND) application submitted to the U.S. Food and Drug administration (FDA)Plans in place to initiate a Human clinical trial in 60 healthy volunteers in the...
ABVC BioPharma Provides Vitargus® Update - Phase II Vitargus® Study Protocol Received Thai FDA Approval
17 nov. 2022 08h30 HE
|
ABVC BioPharma, Inc.
FREMONT, CA, Nov. 17, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
LiquidPiston Awarded Phase II Army Contract to Advance Hybrid Electrification for Unmanned Aerial Vehicles (UAVs)
13 sept. 2022 09h00 HE
|
LiquidPiston
BLOOMFIELD, Conn., Sept. 13, 2022 (GLOBE NEWSWIRE) -- LiquidPiston, Inc., the leading innovator of efficient engine technology and hybrid power systems, today announced a $1.7 million Phase II award...
HOOKIPA Announces First Patient Enrolled in Phase 2 Trial Evaluating HB-200 and Pembrolizumab for Treatment of Head and Neck Cancer and Reports FDA’s Fast Track Designation
18 janv. 2022 07h00 HE
|
HOOKIPA Pharma Inc.
First patient dosed with HB-200 and pembrolizumab combination for treatment of 1st-line advanced/metastatic head and neck cancer in Phase 2 arm of ongoing Phase 1/2 trial Fast Track Designation...
Earth Science Tech, Inc. (ETST) Executes Phase I Acquisition of RxCompoundStore.com, LLC. and Peaks Curative, LLC.
04 nov. 2021 09h00 HE
|
Earth Science Tech, Inc.
DORAL, FL, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), an innovative biotech company focused in nutraceutical and pharmaceutical fields, and...
Arch Biopartners Receives Health Canada Approval to Conduct COVID-19 Phase II Human Trial
08 mai 2020 06h00 HE
|
Arch Biopartners
TORONTO, May 08, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating...
Enrolment of first patient in Phase II trial testing DNV3837 in Clostridioides difficile infections
27 janv. 2020 01h30 HE
|
Deinove
Enrolment of first patient in Phase II trial testing DNV3837 in Clostridioides difficile infections The Phase II clinical trial aims to evaluate the efficacy, safety and pharmacokinetics of DNV3837...
American BriVision Announces Issuance of a Full Clinical Study Report (CSR) for ABV-1504 for Major Depressive Disorder Phase II Study
14 nov. 2019 13h22 HE
|
American BriVision Holding Corporation
PDC-1421 high-dose data meets primary endpoint on MADRS scale in ITT clinical trial population PDC-1421 low-dose and PDC-1421 high-dose each proved safe, were well-tolerated, and had no...
Pharmacovigilance Market will register 10.7% CAGR to cross $8.0 billion by 2024: Global Market Insights, Inc.
25 sept. 2018 07h00 HE
|
Global Market Insights, Inc
Sellbyville, Delaware, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Global Pharmacovigilance Market will surpass USD 8.0 billion by 2024; according to a new research report by Global Market Insights, Inc....
Breathtec to Open New Drug Development Division, Signs LOI to acquire 100% of Clinical Stage Nash Pharmaceuticals Inc.
02 août 2018 07h00 HE
|
Breathtec Biomedical Inc.
VANCOUVER, British Columbia, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company”) is pleased to announce that it will be...